Drug safety describes to the potential for adverse effects that are related to the administration of drugs. Key challenges in drug discovery and development are identifying and solving potential safety problems as early as possible in the nonclinical or clinical setting. Advancements in the approaches used to characterize toxicities have resulted in identification of safety biomarkers and clear opportunities to aid in understanding mechanisms of clinically-important adverse drug reactions. The unique goal of the science applied to drug safety is to improve the benefit-risk ratio of investigational drugs and ultimately, improve the safety profiles and tolerability of therapies. The session themes will highlight various concepts and approaches that are addressing the key challenges in drug safety. A unique attribute of the Drug Safety GRC is the specific intent to create science-based partnerships among drug safety scientists and experts from many disciplines.
The conference will consist of nine sessions, on the topics listed below. The conference chair is currently developing their preliminary program, which will include the names of the invited speakers and discussion leaders for each of these sessions. The preliminary program will be available by October 15, 2019. Please check back for updates.
- Keynote Session: Modeling Complex Biological Systems
- Emerging Applications of Big Data and Machine Learning in Safety Assessment
- Leveraging Human Genetics and Big Data to Inform Drug Safety
- Biomarker Science in Drug Discovery and Development
- Microphysiological Models: Advances in Modeling Complex In Vivo Functions and Organ Responses
- Improving Nonclinical Paradigms in Safety Assessment
- Novel Therapeutic Modalities: Challenges and Opportunities in Nonclinical Safety Assessment Strategies
- Full Utilization of the Clinical Experience in the Nonclinical Space
- Keynote Session: Advancing Drug Safety Through Innovation